UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia

Hoelzer, D; Bassan, R; Boissel, N; Roddie, C; Ribera, JM; Jerkeman, M; ESMO Guidelines Committee; (2023) ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia. Annals of Oncology 10.1016/j.annonc.2023.09.3112. (In press).

[thumbnail of 1-s2.0-S0923753423040097-main.pdf] Text
1-s2.0-S0923753423040097-main.pdf - Accepted Version
Access restricted to UCL open access staff until 12 October 2024.

Download (1MB)

Abstract

The introduction of immunotherapy with monoclonal antibodies (mAbs) is a major step forward for adults and children with B-lineage acute lymphoblastic leukaemia (ALL) and will change the treatment paradigm substantially. With intensive multi-agent chemotherapy (ChT) in children with ALL, long-term cure has been achieved in ≥90% of patients; however, this approach is often associated with long-term sequelae. Until recently, aggressive ChT has also been used in adult patients, with an overall cure rate of 50%. Survival rates are higher (∼70%) in adolescents and young adults (AYAs) but lower (<20%) in elderly patients. The major hazard of treatment is myelotoxicity leading to infection, which causes death in the induction and consolidation phases in 1%-3% of children and ≤10% of adults, increasing to ≤20% of elderly patients aged >70 years. With haematopoietic stem cell transplantation (HSCT), cure can be achieved in approximately half of adults; however, this approach is also associated with substantial toxicity and treatment-related mortality (TRM) rates of 10%-20%.

Type: Article
Title: ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
Location: England
DOI: 10.1016/j.annonc.2023.09.3112
Publisher version: https://doi.org/10.1016/j.annonc.2023.09.3112
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Acute lymphoblastic leukaemia; ESMO Clinical Practice Guideline update; immunotherapy; treatment; tyrosine kinase inhibitors
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/10179650
Downloads since deposit
1Download
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item